MacroGenics Q3 net income $56.3M; cash runway into 2026; MARGENZA sale progress

MACROGENICS INC

2024-Q3 EPS reported -$0.82 revenue$130,609,000

Net income $56.3M ($0.90 diluted EPS) vs $17.6M in Q3 2023; revenue $110.7M driven by $100M Incyte milestone.
Cash $200.4M at Sep 30; plus $40M MARGENZA upfront from TerSera, less $8M fee; runway into 2026.
MARGENZA sale to TerSera for $40M upfront + up to $35M milestones; closing expected Q4 2024.
IND for ADAM9-targeting ADC MGC028 submitted; TAMARACK mCRPC study continues, rPFS data early 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.